Intervention Protocol

Safety of off-label erythropoiesis-stimulating agents for critically ill patients

  1. Bita Mesgarpour1,2,
  2. Benedikt H Heidinger2,
  3. Dominik Roth2,
  4. Susanne Schmitz3,
  5. Cathal D Walsh4,
  6. Harald Herkner2,*

Editorial Group: Cochrane Anaesthesia Group

Published Online: 12 FEB 2014

DOI: 10.1002/14651858.CD010969


How to Cite

Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Safety of off-label erythropoiesis-stimulating agents for critically ill patients (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010969. DOI: 10.1002/14651858.CD010969.

Author Information

  1. 1

    Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

  2. 2

    Medical University of Vienna, Department of Emergency Medicine, Vienna, Austria

  3. 3

    Trinity College Dublin, Department of Pharmacology & Therapeutics, Dublin, Ireland

  4. 4

    Trinity College Dublin, Department of Statistics, Dublin, Ireland

*Harald Herkner, Department of Emergency Medicine, Medical University of Vienna, Allgemeines Krankenhaus, Währinger Gürtel 18-20,, Vienna, 1090, Austria. harald.herkner@meduniwien.ac.at.

Publication History

  1. Publication Status: New
  2. Published Online: 12 FEB 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

With a focus on safety, we aim to assess the effects of ESAs (ESAs alone or in combination) compared with placebo, no treatment or a different active treatment regimen when administered off-label to critically ill patients. We will further describe and explore heterogeneity and will assess the influence of bias on the robustness of our effect estimates.